u/Fine-Aioli9525

The author argues iHuman (IH) holds a net cash position of roughly $3.20 per share while the stock trades near $1.20, so a DCF adding value of operations to net cash yields intrinsic value well above the current price. The mechanism is a cash-rich balance sheet plus an expected new long-term growth phase that the author believes will drive a re-rating. The stated catalyst/horizon is the next 12 months, framed as one of the biggest return stories; the author gives no explicit risk beyond noting it is not investment advice.